Effectiveness, Tolerability, and Safety of Different Amphotericin B Formulations in Invasive Fungal Infections: A Multicenter, Retrospective, Observational Study

Cavassin, Francelise Bridi; Magri, Marcello Mihailenko Chaves; Vidal, Jose Ernesto; Carlesse, Fabianne Altruda de Moraes Costa; Falci, Diego Rodrigues; Carneiro, João Luís Baú-; Breda, Giovanni Luís; Motta, Fábio de Araújo; Godoy,  Cássia Silva de Miranda; Soares, Renata de Bastos Ascenço; Oliveira, Carla Sakuma De; Mendes, Ana Verena Almeida; Morales, Hugo Paz; Montes, Patrícia Silva; Rego, Caroline Martins; Félix,  Maíra Araujo; Katopodis, Paula Pacheco; Ó, Julia Raquel da Silva do; Abrão, Mirela Pereira Lima Mirela Pereira Lima; Pereira, Talita Teles Teixeira; Telles, Flávio Queiroz-

Purpose:

Data on the real-life use of amphotericin B lipid complex (ABLC) compared with other available formulations are limited. This study aimed to evaluate the effectiveness, tolerability, and safety of different amphotericin B (AMB) intravenously administered in the context of hospital practice for the treatment of invasive fungal infections (IFI) and to provide new insights into the profile of ABLC.

Methods:

This is a multicenter, retrospective, observational study conducted at 10 tertiary Brazilian hospitals. Patients first exposed to any formulation of AMB for treating endemic and opportunistic IFI who had received at least 2 intravenous doses were screened. Retrospective data (from January 2014 to December 2019) were extracted from the patients' medical records. Clinical parameters were examined pre- and post-treatment to determine effectiveness; acute infusion-related side effects (IRSE) and drug interruption to determine tolerability; and adverse events, toxicity, and treatment interruption were stated to analyze safety.